GlobeNewswire Inc | Dec 11, 2020 01:00AM EST

December 11, 2020

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly

-- Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years -- Insufficient response in older adults demonstrates the need to refine the concentration of antigen in order to provide high-level immune response across all age groups -- Companies plan a Phase 2b study with an improved antigen formulation -- With support from BARDA as part of Operation Warp Speed, study to start in February 2021, including a proposed comparison with an authorized COVID-19 vaccine -- Product availability now expected in Q4 2021 pending successful completion of the development plan

PARIS and LONDON December 11, 2020 Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase 1/2 study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response in older adults likely due to an insufficient concentration of the antigen.

A recent challenge study in non-human primates performed with an improved antigen formulation demonstrated that the vaccine candidate could protect against lung pathology and lead to rapid viral clearance from the nasal passages and lungs, within 2 to 4 days. These results increase the Companies confidence in the capacity of the adjuvanted recombinant platform to deliver a highly efficient vaccine for all adults.

Sanofis recombinant technology and GSKs pandemic adjuvant are established vaccine platforms that have proven successful against influenza. The recombinant technology offers the advantages of stability at temperatures used for routine vaccines, the ability to generate high and sustained immune responses, and the potential to prevent virus transmission.

We care greatly about public health which is why we are disappointed by the delay announced today, but all our decisions are and will always be driven by science and data. We have identified the path forward and remain confident and committed to bringing a safe and efficacious COVID-19 vaccine. Following these results and the latest encouraging new preclinical data, we will now work to further optimize our candidate to achieve this goal, said Thomas Triomphe, Executive Vice President and Head of Sanofi Pasteur. No single pharma company can make it alone; the world needs more than one vaccine to fight the pandemic.

Roger Connor, President of GSK Vaccines added The results of the study are not as we hoped. Based on previous experience and other collaborations, we are confident that GSKs pandemic adjuvant system, when coupled with a COVID-19 antigen, can elicit a robust immune response with an acceptable reactogenicity profile. It is also clear that multiple vaccines will be needed to contain the pandemic. Our aim now is to work closely with our partner Sanofi to develop this vaccine, with an improved antigen formulation, for it to make a meaningful contribution to preventing COVID-19.

The Companies plan a Phase 2b study expected to start in February 2021 with support from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) under contract W15QKN-16-9-1002. The study will include a proposed comparison with an authorized COVID-19 vaccine. If data are positive, a global Phase 3 study could start in Q2 2021. Positive results from this study would lead to regulatory submissions in the second half of 2021, hence delaying the vaccines potential availability from mid-2021 to Q4 2021.

Sanofi and GSK adjuvanted recombinant protein-based vaccine candidate was selected in July 2020 by U.S. governments Operation Warp Speed in order to accelerate its development and manufacturing.

The Companies have updated Governments and the European Commission where a contractual commitment to purchase the vaccine has been made.

Phase 1/2 study

The interim Phase 1/2 results showed a level of neutralizing antibody titers after two doses comparable to sera from patients who recovered from COVID-19, a balanced cellular response in adults aged 18 to 49 years, but insufficient neutralizing antibody titers in adults over the age of 50. The candidate showed transient but higher than expected levels of reactogenicity likely due to the suboptimal antigen formulation, with no serious adverse events related to the vaccine candidate. The most favorable results were observed in the group which tested the highest antigen concentration, combined with the GSK adjuvant, showing neutralization titers in 88% of participants. Seroconversion was observed in 89.6% of the 18 to 49 age group; 85% in the >50 age group; and 62.5% in the >60 age group.

The Phase 1/2 clinical study is a randomized, double blind and placebo-controlled study designed to evaluate the safety, reactogenicity and immunogenicity (immune response) of the COVID-19 vaccine candidate. A total of 441 healthy adults participated in the study, across 10 investigational sites in the United States. The participants received one or two doses of the vaccine candidate, or placebo at 21 days apart.

Full results of the Phase 1/2 study will be published as soon as all data are available, following peer-reviewed publication process.

Latest preclinical results

A recent preclinical study using a highly virulent challenge in non-human primates, showed high ability for the vaccine to protect against lung pathology and reduce virus in the nose and lungs within 2 to 4 days. Results from this pre-clinical study confirm strong ability of the vaccine candidate to stop the replication of the virus with an optimal antigen formulation.

These data are being prepared for submission to a peer-reviewed publication.

On the front lines in the fight against COVID-19

In addition to the recombinant protein-based vaccine in collaboration with GSK, Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio. Preclinical data showed that two immunizations of the mRNA vaccine induced high neutralizing antibody levels that are comparable to the upper range of those observed in infected humans. Sanofi expects the Phase 1/2 study to start in Q1 2021, with earliest potential approval in the second half of 2021.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the leading manufacturer of vaccines globally. For further information please visit www.gsk.com



About Sanofi

Sanofi is dedicated to supporting people through their health challenges. Weare a global biopharmaceutical company focused on human health. We preventillness with vaccines, provide innovative treatments to fight pain and easesuffering. We stand by the few who suffer from rare diseases and the millionswith long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transformingscientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Sanofi Media Relations Sanofi Investor Relations - ParisQuentin Vivant Eva Schaefer-JansenTel.: +33 (0)1 53 77 46 46 Arnaud DelepineQuentin.Vivant@sanofi.com Yvonne Naughton



Ashleigh Koss Sanofi Investor Relations ? North AmericaTel.: +1 (908) 205-2572 Felix LauscherAshleigh.Koss@sanofi.com Fara Berkowitz Suzanne Greco

Nicolas KressmannTel.: +1 (732) 532 53-18 IR Main Line:Nicolas.Kressmann@sanofi.com Tel.: +33 (0)1 53 77 45 45 investor.relations@sanofi.com

Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in thePrivate Securities Litigation Reform Act of 1995, as amended. Forward-lookingstatements are statements that are not historical facts. These statementsinclude projections and estimates and their underlying assumptions, statementsregarding plans, objectives, intentions and expectations with respect to futurefinancial results, events, operations, services, product development andpotential, and statements regarding future performance. Forward-lookingstatements are generally identified by the words ?expects?, ?anticipates?,?believes?, ?intends?, ?estimates?, ?plans? and similar expressions. AlthoughSanofi?s management believes that the expectations reflected in suchforward-looking statements are reasonable, investors are cautioned thatforward-looking information and statements are subject to various risks anduncertainties, many of which are difficult to predict and generally beyond thecontrol of Sanofi, that could cause actual results and developments to differmaterially from those expressed in, or implied or projected by, theforward-looking information and statements. These risks and uncertaintiesinclude among other things, the uncertainties inherent in research anddevelopment, future clinical data and analysis, including post marketing,decisions by regulatory authorities, such as the FDA or the EMA, regardingwhether and when to approve any drug, device or biological application that maybe filed for any such product candidates as well as their decisions regardinglabelling and other matters that could affect the availability or commercialpotential of such product candidates, the fact that product candidates ifapproved may not be commercially successful, the future approval and commercialsuccess of therapeutic alternatives, Sanofi?s ability to benefit from externalgrowth opportunities, to complete related transactions and/or obtain regulatoryclearances, risks associated with intellectual property and any related pendingor future litigation and the ultimate outcome of such litigation, trends inexchange rates and prevailing interest rates, volatile economic and marketconditions, cost containment initiatives and subsequent changes thereto, andthe impact that COVID-19 will have on us, our customers, suppliers, vendors,and other business partners, and the financial condition of any one of them, aswell as on our employees and on the global economy as a whole. Any materialeffect of COVID-19 on any of the foregoing could also adversely impact us. Thissituation is changing rapidly, and additional impacts may arise of which we arenot currently aware and may exacerbate other previously identified risks. Therisks and uncertainties also include the uncertainties discussed or identifiedin the public filings with the SEC and the AMF made by Sanofi, including thoselisted under ?Risk Factors? and ?Cautionary Statement Regarding Forward-LookingStatements? in Sanofi?s annual report on Form 20-F for the year ended December31, 2019. Other than as required by applicable law, Sanofi does not undertakeany obligation to update or revise any forward-looking information orstatements.

Attachment

-- PDF